Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N3O |
Molecular Weight | 281.3523 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(O)=CC=C3
InChI
InChIKey=MRBDMNSDAVCSSF-UHFFFAOYSA-N
InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
Molecular Formula | C17H19N3O |
Molecular Weight | 281.3523 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030
Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6124636 |
3.7 nM [Kd] | ||
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886664 |
16.6 nM [Kd] | ||
Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6330361 |
5.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | REGITINE Approved UsePhentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. Launch Date-5.6557437E11 |
|||
Primary | REGITINE Approved UsePhentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. Launch Date-5.6557437E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
67.05 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24452521 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENTOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
197.59 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24452521 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENTOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.32 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24452521 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENTOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Disc. AE: Rhinitis, Vomiting... AEs leading to discontinuation/dose reduction: Rhinitis Sources: Page: p.268Vomiting Nausea Diarrhea Headache Dizziness Tachycardia |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Disc. AE: Dyspnea, Tachycardia... AEs leading to discontinuation/dose reduction: Dyspnea (0.84%) Sources: Page: S51Tachycardia (0.84%) Epistaxis (0.84%) Cephalgia (0.84%) Flushing (serious, 0.84%) Chest pain (serious, 0.84%) Shortness of breath (serious, 0.84%) Tachycardia (serious, 0.84%) |
5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Disc. AE: Myocardial infarction, Cerebrovascular spasm... AEs leading to discontinuation/dose reduction: Myocardial infarction Sources: Cerebrovascular spasm Cerebral vascular occlusion Hypotension |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Dizziness | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Headache | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Nausea | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Rhinitis | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Tachycardia | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Vomiting | Disc. AE | 80 mg 10 times / month multiple, oral Highest studied dose Dose: 80 mg, 10 times / month Route: oral Route: multiple Dose: 80 mg, 10 times / month Sources: Page: p.268 |
unhealthy, 26–83 n = 691 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 26–83 Sex: M Population Size: 691 Sources: Page: p.268 |
Cephalgia | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Dyspnea | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Epistaxis | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Tachycardia | 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Chest pain | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Flushing | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Shortness of breath | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Tachycardia | serious, 0.84% Disc. AE |
40 mg 1 times / day multiple, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: S51 |
unhealthy, 28–80 n = 119 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 28–80 Sex: M Population Size: 119 Sources: Page: S51 |
Cerebral vascular occlusion | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Cerebrovascular spasm | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Hypotension | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
Myocardial infarction | Disc. AE | 5 mg single, intravenous|intramuscular Recommended Dose: 5 mg Route: intravenous|intramuscular Route: single Dose: 5 mg Sources: |
unhealthy Health Status: unhealthy Condition: Pheochromocytoma Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Positive phentolamine test in hypertension induced by a nasal decongestant. | 1969 Apr 17 |
|
Use of phentolamine in acute myocardial infarction associated with hypertension and left ventricular failure. | 1973 Apr |
|
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats. | 1975 |
|
[Effect of several neuroleptic, adreno-, sympatho- and cholinolytic substances on the development of experimental cerebral edema induced by nicotine]. | 1977 May-Jun |
|
A study of the sympathomimetic action of guanethidine on the isolated anococcygeus muscle of the rat. | 1978 Feb |
|
Three cases of sinoatrial block induced by anticonvulsants. | 1978 Jul |
|
Central action of narcotic analgesics. Part III. The role of endogenous noradrenaline in hyperactivity induced by morphine or fentanyl in mice. | 1978 Jul-Aug |
|
Oral therapy with phentolamine in chronic congestive heart failure. | 1979 Apr |
|
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction. | 1979 Feb |
|
Noradrenergic influences on sound-induced seizures. | 1980 Aug |
|
Effects of clonidine on canine cardiac neuroeffector structures controlling heart rate. | 1980 Oct |
|
Electrophysiologic properties of hydralazine in man. | 1980 Sep |
|
Noninvasive assessment of load reduction in chronic congestive heart failure patients. | 1981 Aug |
|
Hypertensive crisis resulting from avocados and a MAO inhibitor. | 1981 Nov |
|
Mediation of renin release in essential hypertension by alpha-adrenoreceptors. | 1981 Nov-Dec |
|
Alpha-adrenoceptor blockade by phentolamine causes beta-adrenergic vasodilation by increased catecholamine release due to presynaptic alpha-blockade. | 1982 Jan-Feb |
|
The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries: inhibition with phentolamine. | 1982 Mar |
|
Some functional changes in experimentally induced cardiac overload. | 1983 |
|
Role of autonomic nervous system in the pathogenesis of angina pectoris. | 1983 Feb |
|
A nonhuman primate model for evaluating the potential of antihypertensive drugs to cause orthostatic hypotension. | 1983 May |
|
Involvement of adenosine receptor activities in aggressive responses produced by clonidine in mice. | 1984 |
|
Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats. | 1984 Mar |
|
Dissociation of epinephrine's hyperglycemic and anorectic effect. | 1985 Mar |
|
Hypertension after epidural meperidine. | 1985 Nov |
|
Sympathetic mechanisms in poststenotic myocardial ischemia. | 1986 |
|
Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. | 1988 Apr |
|
Complications of phenylpropanolamine. | 1989 Apr |
|
Propranolol antagonizes hypotension induced by alpha-blockers but not by sodium nitroprusside or methacholine. | 1989 Feb |
|
Treatment of peripheral ischemia secondary to lidocaine containing epinephrine. | 1989 Jul |
|
An improved vasoactive drug combination for a pharmacological erection program. | 1991 Dec |
|
Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit. | 1993 Jul |
|
Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. | 1993 May |
|
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice. | 1993 Oct 15 |
|
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. | 1994 Jan 24 |
|
Reasons for high drop-out rate with self-injection therapy for impotence. | 1994 Sep |
|
Involvement of the sympathetic postganglionic neuron in capsaicin-induced secondary hyperalgesia in the rat. | 1995 Mar |
|
Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alpha-methyl-5-hydroxytryptamine plus noradrenaline. | 1996 Apr 22 |
|
Cocaine-associated myocardial infarction. | 1996 Aug |
|
Neural mechanism of pressor action of nitric oxide synthase inhibitor in anesthetized monkeys. | 1996 Sep |
|
[Effect of morphine chloride on contractility of small intestinal muscle in vitro or in vivo and its mechanisms]. | 2008 May |
|
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. | 2009 Nov 1 |
|
Limited clinical value of bacterial cocaine esterase in cocaine toxicity. | 2010 May |
|
Phentolamine mesylate for accelerating recovery from lip and tongue anesthesia. | 2010 Oct |
|
Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions. | 2011 Jul |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Insights into the mechanisms mediating hyperglycemic and stressogenic outcomes in rats treated with monocrotophos, an organophosphorus insecticide. | 2012 Mar 29 |
|
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. | 2012 Oct |
|
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. | 2013 Dec |
|
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma. | 2013 Dec 15 |
|
Acute effects of a sarin-like organophosphorus agent, bis(isopropyl methyl)phosphonate, on cardiovascular parameters in anaesthetized, artificially ventilated rats. | 2013 Oct 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/phentolamine.html
Prevention or control of hypertensive episodes in the patient with pheochromo-cytoma. For preoperative reduction of elevated blood pressure, 5 mg of Phentolamine mesylate (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary.
During surgery, Phentolamine mesylate (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of hypertension, tachycardia, respiratory depression, convulsions, or other effects of epinephrine intoxication.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26180030
Cancer cell lines, PC-3, DU-145, NCI/ADR-RES, and SKOV3 were used for activity evaluation. Cells were seeded in 96-well plates. After 24 hr,
cells were fixed with 10% trichloroacetic acid (TCA) representing cell population at time zero (T0). After additional incubation of 0.1% DMSO or phentolamine for 48 hr, cells were fixed with 10% TCA and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out. SRB bound cells were solubilized with 10mM Trizma base.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:51:33 UTC 2022
by
admin
on
Fri Dec 16 16:51:33 UTC 2022
|
Record UNII |
Z468598HBV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV03AB36
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
||
|
NDF-RT |
N0000175553
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
||
|
WHO-ATC |
C04AB01
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
||
|
WHO-ATC |
V03AB36
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
||
|
NDF-RT |
N0000000099
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
||
|
WHO-VATC |
QC04AB01
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C62066
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
DTXSID4023462
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
8153
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | RxNorm | ||
|
5775
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
50-60-2
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
D010646
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
502
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
Z468598HBV
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
Z468598HBV
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
DB00692
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
3382
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
M8646
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | Merck Index | ||
|
PHENTOLAMINE
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
8081
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
SUB09785MIG
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
22
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
CHEMBL597
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
2142
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY | |||
|
200-053-1
Created by
admin on Fri Dec 16 16:51:33 UTC 2022 , Edited by admin on Fri Dec 16 16:51:33 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||